The Latest Cardiac and Vascular News
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo’s 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, chairman and chief executive officer, and Dr. Brad Sutton, chief medical officer, Atrial…
-FDA requires additional time to complete its review of ATEV™ (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma-
SARASOTA, Fla., Aug. 13, 2024 /PRNewswire/ — Spectrum Dynamics Medical, a leading innovator in digital SPECT-CT imaging solutions, announced that its partnering with DEEPDENSE Medical, developing innovative AI-based clinical applications to revolutionize Cardiac and Spine disease…
• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024.
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2024.
August 07, 2024 08:00 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation, announced today the closing of $16 million Series B financing. The round, led by the MedTech & Irrus Syndicates, included […]
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $100 million to the Company, before deducting placement agent fees and other private placement expenses.
July 31, 2024 04:01 PM Eastern Daylight Time LAGUNA HILLS, Calif. & NEW YORK–(BUSINESS WIRE)–Adagio Medical, Inc. (“Adagio Medical”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD; or “ARYA IV”), […]
